Gilead Sciences: two insiders report 3,000-share sales on October 15
Gilead Sciences disclosed Form 4 filings on October 16, 2026, reporting that two company officers sold 3,000 common shares each at $156.22 per share on October 15, 2026, under 10b5-1 trading plans.
Johanna Mercier's sale and post-trade holding
Johanna Mercier, Gilead's Chief Commercial and Corporate Affairs Officer, sold 3,000 shares at $156.22 on October 15, 2026, with the transaction disclosed in a Form 4 filed October 16, 2026. After the trade, Mercier directly held 113,684 common shares, according to the filing summary published by Kalkine Media.
Andrew Dickinson's same-day 3,000-share sale
Andrew Dickinson, Chief Financial Officer of Gilead Sciences Inc (NASDAQ: GILD), sold 3,000 shares on October 15, 2026, according to a separate SEC Form 4 filing summarized by GuruFocus on October 16, 2026. The trade was executed at an average price of $156.22, consistent with the price reported for Mercier's filing.
10b5-1 plan context and disclosure timing
The two sales were both characterized in the source materials as carried out under pre-arranged 10b5-1 trading plans, with the filings appearing on the U.S. Securities and Exchange Commission's Form 4 system the business day after execution. The October 16, 2026, disclosure date falls within the two-business-day Form 4 reporting window that applies to changes in officer beneficial ownership.
Follow-up signals
Additional Form 4 filings from Gilead Sciences insiders, or any subsequent amendments, would be the next verifiable disclosure point on the U.S. SEC's insider transaction feed.
Share this article
